$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company...
Hence then, the article about atossa therapeutics announces closing of registered direct offering of up to 16 5 million in gross proceeds was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds )
Also on site :
- An Award-Winning Restaurant Chef Is Begging People to Stop Doing This One Thing With Chicken—and Do This Instead
- Macy's 'Gorgeous' 40%-Off Halo Birthstone Earrings Are a Personalized Way to 'Look Like a Million Bucks'
- Badger Meter Deadline Tomorrow: BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit